Hyperprolactinemia (hPRL) often poses a diagnostic dilemma due to the presence of macroprolactin. Understanding the prevalence of macroprolactinemia (mPRL) has an important implication in managing patients with hPRL. The primary aim of this study was to determine the prevalence of mPRL globally and to explore selected factors influencing the prevalence estimate. Studies with original data related to the prevalence of mPRL among patients with hPRL from inception to March 2020 were identified, and a random effects meta-analysis was performed. Of the 3770 records identified, 67 eligible studies from 27 countries were included. The overall global prevalence estimate was 18.9% (95% CI: 15.8%, 22.1%) with a substantial statistical heterogeneity (I² = 95.7%). The highest random effects pooled prevalence was observed in the African region (30.3%), followed by Region of the Americas (29.1%), European (17.5%), Eastern Mediterranean (13.9%), South-East Asian (12.7%), and Western Pacific Region (12.6%). Lower prevalence was observed in studies involving both sexes as compared to studies involving only female participants (17.1% vs. 25.4%) and in more recent studies (16.4%, 20.4%, and 26.5% in studies conducted after 2009, between 2000 and 2009, and before 2000, respectively). The prevalence estimate does not vary according to the age group of study participants, sample size, and types of polyethylene glycol (PEG) used for detection of macroprolactin (PEG 6000 or PEG 8000). With macroprolactin causing nearly one-fifth of hPRL cases, screening for mPRL should be made a routine before an investigation of other causes of hPRL.

Background: In end-stage renal disease (ESRD), troponin T concentrations can be elevated even without cardiac ischaemia, which hampers the diagnosis of acute myocardial infarction (AMI). The objectives of our study were to determine the proportion of dialysis-dependent ESRD patients without acute coronary syndrome (ACS) but with highly sensitive cardiac troponin T (hs-cTnT) levels above the 99th percentile upper reference limit and to evaluate the range of hs-cTnT among this population. Methods: A cross-sectional study was conducted at the haemodialysis (HD) unit of a tertiary hospital in Malaysia from January 2018 to February 2019. Dialysis-dependent ESRD patients were included and those with a recent history of ACS (within 30 days) were excluded. Pre-dialysed serum hs-cTnT levels were measured using Cobas e411. The upper limit of the 99th percentile value for troponin T was 14 ng/L. Results: A total of 150 patients were recruited as study participants. The majority were female (62%) and of Malay ethnicity (94%), and the mean (SD) age was 45.19 (16.36) years old. The hs-cTnT range (min, max) was 11.39-738.30 ng/L and the median (interquartile range [IQR]) of hs-cTnT was 59.20 (83.41) ng/L. Elevated hs-cTnT levels were observed in 149/150 (99%) of the study participants (54/55 [98.2%] of the patients were on HD, and 95/95 [100.0%] of the patients were on continuous ambulatory peritoneal dialysis). Conclusion: This study supports prior research showing that even without ACS, most ESRD patients have elevated concentrations of cardiac troponin. Furthermore, our study illustrates the need to revisit the use of absolute troponin values when making a diagnosis of ACS in ESRD patients.

Background: As an early recognition of neonatal sepsis is important for triggering the initiation of treatment, this study was thus designed to assess the diagnostic performance and discrimination value of procalcitonin (PCT) in neonatal sepsis cases. Methods: This cross-sectional study, which was carried out at the Paediatric Intensive Care Unit of Hospital Universiti Sains Malaysia (HUSM) in Kelantan, Malaysia, had involved 60 neonates admitted for suspected sepsis. Sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV) and the area under receiver operating characteristics curve (AUC) for PCT were determined at initial presentation (0h) as well as 12 h and 24 h after presentation in comparison to blood culture as the gold standard. Results: The study consisted of 27 (45.0%) male and 33 (55.0%) female neonates with a mean (SD) age of 76.8 (48.25) h. At cut-off PCT value of > 2 ng/mL, the sensitivity, specificity, PPV and NPV were 66.7%, 66.7%, 33.3% and 88.9% at 0 h. The respective parameters were 83.3%. 56.3%, 32.3% and 93.1% at 12 h and 83.3%, 52.1%, 30.3% and 92.6% at 24 h. AUC was 71.6%, 76.6% and 7 1.7 % at 0 h, 12 h and 24 h. Conclusions: Diagnostic performance and discrimination values of PCT for diagnosis of neonatal sepsis varied with time of obtaining the blood samples. The Per result at 12 h demonstrates the most optimal diagnostic performance and discrimination values.

ObjectivesMacroprolactinaemia is a known benign cause of hyperprolactinaemia (hyperPRL). Differentiating macroprolactinaemia and hyperPRL is important, as macroprolactinaemia does not require treatment. This study was conducted to determine the prevalence of macroprolactinaemia among hyperPRL patients through the use of polyethylene glycol 8000.MethodsFrom 2011 to 2013, a cross-sectional study was conducted on patients diagnosed with hyperPRL in Hospital Universiti Sains Malaysia (HUSM). Sera from these patients were measured for PRL using cobas e411 (Roche Diagnostics, Indianapolis, USA) (sandwich principle) and the same sera were treated with polyethylene glycol (PEG) 8000 to differentiate true hyperPRL from macroprolactinaemia. PRL recovery of less than 40% was used as an indicator of the presence of macroprolactin.ResultsA total of 133 hyperPRL patients, 120 (90%) women and 13 (9.8%) men, aged 18–68 years, with mean (standard deviation) age 34.37 (11.75) years comprised this study cohort. Nine female patients were found to have macroprolactinaemia with an estimated prevalence of 6.8% (95% CI: 2.4%, 11.1%).ConclusionsThe prevalence of macroprolactinaemia detected using PEG 8000 among patients diagnosed as hyperPRL was low. Screening for macroprolactin using PEG 8000 indicated that the majority of patients who presented with hyperPRL in HUSM were true hyperPRL

Infertility affects millions of people of reproductive age worldwide. Thyroid hormones and prolactin (PRL) affect reproduction and pregnancy; therefore, these two hormones influence fertility. This systematic review and meta-analysis aimed to summarise the strength of the correlation between serum PRL and thyroid stimulating hormone (TSH) in infertile women and to explore selected factors influencing the correlation. We conducted a systematic search of online databases (PubMed, Scopus, ScienceDirect, SAGE and Google Scholar) from inception until March 2021 and a manual search of the bibliographies of the included studies to identify relevant publications. The original research paper describing the correlation between PRL and TSH in reproductive-age women with infertility (primary and secondary) was included. The risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. A random effect model was used to estimate the pooled correlations of PRL and TSH, followed by an assessment of heterogeneity and a sensitivity analysis. From a total of 822 relevant articles identified, 11 were eligible and included in this systematic review and metaanalysis. The random effect pooled correlation estimates between PRL and TSH was 0.431 (95% CI: 0.251, 0.582), with substantial heterogeneity between the included studies (I2 = 80%, τ2 = 0.067, P < 0.001). No significant publication bias was observed. Study region, types of infertility, sample size and year of the study did not influence the correlation estimates. Our results highlighted a significant positive moderate correlation between serum PRL and serum TSH in infertile women.